Tudorza Pressair: Dosage, potential adverse effects, applications, and additional details
Chronic Obstructive Pulmonary Disease (COPD) is a condition that affects the lungs, including diseases such as emphysema and chronic bronchitis. Tudorza Pressair, a brand-name prescription drug inhaler, is FDA-approved to treat COPD in adults.
Tudorza Pressair comes as a powder that is inhaled through the mouth and into the lungs, in a dose of 400 micrograms (mcg) per puff. It is usually taken twice a day, about 12 hours apart.
The drug works by relaxing the muscles in the airways, helping to open the airways and make it easier to breathe. In clinical studies, people who used Tudorza Pressair saw an average improvement in forced expiratory volume in 1 second (FEV1) of 0.06 L to 0.10 L, while those who took a placebo saw an average decrease in their FEV1 of 0.01 L to 0.05 L.
It's important to note that Tudorza Pressair should not be used to treat asthma. Oxygen therapy may be prescribed if you have a low oxygen level caused by severe COPD symptoms. With oxygen therapy, you'll use a portable oxygen tank that's connected to a mask or nasal cannula.
Before taking Tudorza Pressair, it's crucial to inform your doctor and pharmacist about all prescription, over-the-counter, and other drugs you take, as well as any vitamins, herbs, and supplements. Tudorza Pressair can interact with several other medications, so it's essential to avoid using it with other drugs that belong to the same drug class, anticholinergics.
The cost of Tudorza Pressair can vary. The actual price you'll pay depends on your insurance plan, your location, and the pharmacy you use. Your insurance plan may require you to get prior authorization before approving coverage for Tudorza Pressair. Financial assistance is available for Tudorza Pressair through the Tudorza Pressair Savings Guarantee Program.
Tudorza Pressair is not currently available in generic form. If you miss a dose, just skip the missed dose. Never take an extra dose to make up for a missed dose.
In comparison to other bronchodilator medications used for the treatment of COPD, such as Spiriva and Anoro Ellipta, Tudorza Pressair is a long-acting muscarinic antagonist (LAMA) requiring twice-daily administration, providing bronchodilation by anticholinergic action. Spiriva is also a LAMA but is usually dosed once daily, which may improve convenience and compliance. Anoro Ellipta combines a LAMA with a long-acting beta-agonist (LABA), offering dual bronchodilation that can be more effective in controlling symptoms in moderate to severe COPD compared to monotherapy with LAMA alone.
In terms of clinical choice, the selection among these depends on the severity of disease, patient preference regarding inhaler device and dosing frequency, and response to treatment. Tudorza Pressair is meant to be used as a long-term treatment because COPD is a lifelong disease that gets worse over time.
[1] COPD Guidelines (Global Initiative for Chronic Obstructive Lung Disease) [5] Tudorza Pressair (aclidinium bromide) Prescribing Information, Sunovion Pharmaceuticals Inc., 2021.
- The medical-condition COPD, which includes diseases such as emphysema and chronic bronchitis, can be treated with the prescription drug Tudorza Pressair, a long-acting muscarinic antagonist (LAMA) that is FDA-approved for adults.
- In respiratory-conditions like COPD, Tudorza Pressair helps by relaxing the muscles in the airways, improving breathing for deciders who use it.
- Science and health-and-wellness professionals should consider Tudorza Pressair as a long-term treatment option for managing COPD, given its unique characteristics, clinical effectiveness, and the need for careful consideration when coordinating other medical-conditions and medications.
